Apimeds Pharmaceuticals US, Inc. (APUS) Key Metrics
APUS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.1M
- Enterprise value
- $17.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
APUS key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAPUS returns How much profit the business earns on the capital it uses.
APUS financial health Debt, liquidity and how easily interest is covered.
APUS valuation history
APUS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
APUS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
APUS price vs earnings per share
APUS key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $17.8M | — | — | — | — |
| Enterprise value | $22.0M | — | — | — | — |
| Price / book | 0.1 | — | — | — | — |
| Earnings yield | −33.6% | — | — | — | — |
| Free cash flow yield | −50.3% | — | — | — | — |
| Share price at fiscal year-end | $16.40 | — | — | — | — |
| Per share | |||||
| Revenue per share | $0.00 | — | — | — | — |
| Earnings per share | −$5.51 | — | — | — | — |
| Operating cash flow per share | −$8.20 | — | — | — | — |
| Free cash flow per share | −$8.26 | — | — | — | — |
| Cash per share | $3.34 | — | — | — | — |
| Book value per share | $140.92 | — | — | — | — |
| Tangible book value per share | $140.92 | — | — | — | — |
| Capex per share | $0.05 | — | — | — | — |
| Debt per share | $7.13 | — | — | — | — |
| Shares outstanding | 1.1M | — | — | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −7.9% | — | — | — | — |
| Return on invested capital (ROIC) | −12.0% | — | — | — | — |
| Return on assets (ROA) | −7.3% | −638.9% | −363.2% | −749.9% | −596.1% |
| Return on tangible assets | −3.7% | — | −184.3% | — | −596.1% |
| Financial health | |||||
| Total debt | $7.8M | $596,844 | $266,891 | $660,000 | $400,000 |
| Cash & short-term investments | $3.6M | $3,455 | $410,481 | $6,171 | $171,438 |
| Net debt | $4.1M | $593,389 | −$143,590 | $653,829 | $228,562 |
| Debt / equity | 0.05 | — | 8.37 | — | — |
| Debt / assets | 0.05 | 45.71 | 0.63 | 106.95 | 2.32 |
| Current ratio | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Quick ratio | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Interest coverage | -42.1 | -10.8 | -19.6 | -21.9 | -151.3 |
| Working capital | $3.3M | −$1.0M | $298,762 | −$313,606 | $161,517 |
| Invested capital | $157.5M | −$764,732 | −$111,719 | −$59,777 | −$9,921 |
| Tangible asset value | $153.3M | −$1.4M | $31,871 | −$713,606 | −$238,483 |
| Net current asset value | $3.1M | −$1.4M | $31,871 | −$713,606 | −$238,483 |
| Graham net-net per share | −$6.62 | — | — | — | — |
| Capital allocation | |||||
| Capex / depreciation | 10.05 | — | — | — | — |
| Efficiency | |||||
| Days payables outstanding | 48,290.5 | — | — | — | — |
| Payables turnover | 0.01 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $754,920 | $591,191 | — | $23,764 | $10,652 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from APUS's annual financial statements (latest annual report filed May 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
APUS valuation and financial ratios
Apimeds Pharmaceuticals US earned a return on equity of −7.9% and a return on invested capital of −12.0% in fiscal 2025. It ended the year with $7.8 million of debt and $3.6 million in cash and short-term investments, net debt of $4.1 million.
See the APUS income statement, the APUS chart for price history, or the APUS stock overview for the latest quote and news.
APUS key metrics FAQ
What is Apimeds Pharmaceuticals US's return on equity?
Apimeds Pharmaceuticals US's return on equity (ROE) was −7.9% in fiscal 2025: net income of -$6.0 million on average shareholders' equity of $76.0 million.
What is Apimeds Pharmaceuticals US's ROIC?
Apimeds Pharmaceuticals US's return on invested capital was −12.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Apimeds Pharmaceuticals US have?
Apimeds Pharmaceuticals US had total debt of $7.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05.
What is Apimeds Pharmaceuticals US's free cash flow yield?
Apimeds Pharmaceuticals US generated -$9.0 million of free cash flow in fiscal 2025, a free cash flow yield of −50.3% on its market value at year-end ($17.8 million).
What is Apimeds Pharmaceuticals US's current ratio?
Apimeds Pharmaceuticals US's current ratio was 1.31 at the end of fiscal 2025: current assets were 1.31 times current liabilities.